Charles Nicolette - Academia.edu (original) (raw)
Papers by Charles Nicolette
Journal of Clinical Oncology, 2017
402 Background: AGS-003 is an autologous tumor RNA-loaded dendritic cell-based immunotherapy bein... more 402 Background: AGS-003 is an autologous tumor RNA-loaded dendritic cell-based immunotherapy being tested in advanced renal cell carcinoma (RCC) patients. The immunologic specificity for the patient’s own tumor is achieved using amplified tumor RNA electroporated into monocyte derived dendritic cells. To produce AGS-003 for RCC patients the RNA is amplified from a 100 mg primary tumor sample obtained via nephrectomy. In this non treatment study we evaluated the feasibility of RNA amplification from MIBC tissue acquired by transurethral resection of bladder tumor (TURBT). Methods: MIBC tissue was obtained via TURBT. Following draining of the irrigant used during the TURBT procedure, tissue was placed into an RNA preservative solution to prevent RNA degradation until processing. Methods developed for the amplification of RCC tumor RNA and RNA quality testing were applied to the RNA extracted from the MIBC specimens. Results: This work demonstrated that the methods developed for the am...
Journal of Clinical Oncology, 2010
e13006 Background: AGS-003 is an autologous immunotherapy prepared from matured monocyte-derived ... more e13006 Background: AGS-003 is an autologous immunotherapy prepared from matured monocyte-derived dendritic cells (DCs) co- electroporated with the subject's own amplified total tumor and synthetic ...
Journal of Clinical Oncology, 2017
402 Background: AGS-003 is an autologous tumor RNA-loaded dendritic cell-based immunotherapy bein... more 402 Background: AGS-003 is an autologous tumor RNA-loaded dendritic cell-based immunotherapy being tested in advanced renal cell carcinoma (RCC) patients. The immunologic specificity for the patient’s own tumor is achieved using amplified tumor RNA electroporated into monocyte derived dendritic cells. To produce AGS-003 for RCC patients the RNA is amplified from a 100 mg primary tumor sample obtained via nephrectomy. In this non treatment study we evaluated the feasibility of RNA amplification from MIBC tissue acquired by transurethral resection of bladder tumor (TURBT). Methods: MIBC tissue was obtained via TURBT. Following draining of the irrigant used during the TURBT procedure, tissue was placed into an RNA preservative solution to prevent RNA degradation until processing. Methods developed for the amplification of RCC tumor RNA and RNA quality testing were applied to the RNA extracted from the MIBC specimens. Results: This work demonstrated that the methods developed for the am...
Journal of Clinical Oncology, 2010
e13006 Background: AGS-003 is an autologous immunotherapy prepared from matured monocyte-derived ... more e13006 Background: AGS-003 is an autologous immunotherapy prepared from matured monocyte-derived dendritic cells (DCs) co- electroporated with the subject's own amplified total tumor and synthetic ...